---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001799"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:30:53.894613+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aptose reports FY 2024 net loss of $25.4M; cash runway to April 2025

## Summary
- Net loss $25.4M vs $51.2M in FY 2023; diluted EPS ($36.38) vs ($227.43).
- Cash and equivalents $6.7M as of Dec 31, 2024; expect funding through April 2025.
- TUS+VEN+AZA triplet TUSCANY trial advancing; 40mg achieved CRs; 80mg dosing started.
- $1.5M of Hanmi debt converted to 409,063 common shares; Hanmi stake capped at 19.99%.
- Regained Nasdaq minimum bid compliance; still not in compliance with $2.5M equity requirement.

## SEC filing metadata
- accession: 0001171843-25-001799
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325001799/0001171843-25-001799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325001799/f8k_032825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001799
- JSON: https://secwatch.observer/filing/0001171843-25-001799.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.